Oova Fertility Monitor: AI-Powered LH and Progesterone Tracking

Personalized hormone baselines, not population averages, may hold the key to solving the puzzle of unexplained infertility for millions of women.

Presented By Our Partners

Standard fertility testing operates on a flawed assumption: that every woman’s hormonal patterns should match a textbook average. The reality is that LH surge magnitude, progesterone adequacy, and cycle timing vary enormously between individuals. A woman whose LH surge peaks at 25 mIU/mL may be perfectly fertile, while another whose surge reaches 60 mIU/mL is equally healthy. Population-level thresholds used by conventional ovulation predictor kits miss this nuance entirely, producing false negatives for women with naturally lower surges and false positives for women with elevated baselines. A 2022 prospective study published in Reproductive Biology and Endocrinology by Yu et al. demonstrated that even advanced machine learning algorithms combining basal body temperature and heart rate achieved only 72.51% accuracy for predicting the fertile window in irregular menstruators, highlighting the fundamental challenge of applying population-level models to individual biology.

The Oova Fertility Monitor takes a different approach. Rather than comparing hormone levels against fixed population thresholds, it uses artificial intelligence to learn each user’s individual hormone patterns and establish personalized baselines, adapting its predictions and confirmations to the specific biology of the woman wearing it.

What Is the Oova Fertility Monitor?

The Oova Fertility Monitor is an FDA-registered at-home urine hormone analyzer that clips onto a smartphone to measure two key reproductive hormones: luteinizing hormone (LH) and progesterone. The device uses proprietary test strips and a smartphone-based optical reader to deliver quantitative hormone concentrations through the Oova app. What distinguishes Oova from other fertility monitors is its AI-driven personalization engine, which learns from each user’s cycle data over time to establish individual hormone baselines rather than relying on population averages.

The system costs $149 for the analyzer attachment, with test strips priced at approximately $49.99 per pack of 10. The app guides users on when to test based on their evolving cycle data, and its AI model refines predictions with each cycle of data collected. Oova’s approach is designed to improve accuracy over time, becoming more personalized as it accumulates individual hormone history.

The device measures both LH (for ovulation prediction) and progesterone (for ovulation confirmation), providing a predict-and-confirm protocol that covers both sides of the ovulatory event. While it does not measure estrogen metabolites or FSH like some competitors, its AI-personalized interpretation of the two hormones it does track represents a distinct approach to fertility intelligence.

The Science Behind Personalized Hormone Analysis

The clinical rationale for personalized hormone baselines is rooted in the well-documented inter-individual variability of reproductive hormone levels. Studies in reproductive endocrinology have consistently shown that LH surge amplitude varies by more than threefold between healthy, fertile women. Progesterone levels during the luteal phase range from 5 to 25 ng/mL in confirmed ovulatory cycles. Using a single population threshold to define “normal” inevitably misclassifies women at both ends of this distribution.

A 2023 study published in Scientific Reports by Pattnaik et al. validated quantitative urinary hormone monitoring across 100 women aged 21 to 45 and found that the most clinically meaningful patterns emerged not from individual data points but from multi-day hormone trajectories. The researchers identified novel hormone trends visible in 94.5% of ovulatory cycles that could only be captured through continuous quantitative tracking. This finding supports Oova’s approach of building longitudinal hormone profiles that capture individual patterns rather than relying on single-threshold detection.

A 2024 systematic review published in the Journal of Medical Internet Research by Lyzwinski et al. examined wearable and at-home reproductive health technologies and found that devices measuring physiological changes could differentiate between menstrual cycle phases with high accuracy. The review emphasized that personalization, adapting algorithms to individual patterns rather than population averages, was emerging as a key differentiator among fertility tracking technologies.

The artificial intelligence component of Oova’s system applies machine learning to the user’s own hormone data, building a model of what “normal” looks like for that specific individual. This approach mirrors the broader trend in precision medicine toward n-of-1 analytics, where treatment decisions and health assessments are based on individual trajectories rather than cross-sectional population data. For fertility monitoring, this means Oova’s system can potentially detect subtle shifts in a user’s hormonal patterns that fixed-threshold systems would miss.

What the Oova Fertility Monitor Does Well

Oova’s AI personalization is its defining strength. By learning each user’s unique hormone patterns over successive cycles, the system can adapt its fertile window predictions and ovulation confirmation criteria to the individual rather than applying one-size-fits-all thresholds. For women whose LH surges are naturally lower or higher than population averages, this personalized approach can mean the difference between accurate and missed ovulation detection.

The dual-hormone approach (LH plus progesterone) provides both prediction and confirmation in a single testing system. Users do not need to purchase separate products for ovulation prediction and confirmation. The smartphone-based design keeps the system portable and avoids the need for a standalone analyzer device, and the app’s guided testing schedule simplifies the protocol by telling users when to test based on their individual cycle data.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Oova’s focus on progesterone alongside LH addresses the critical post-ovulatory gap that LH-only tests leave. Confirming that progesterone rose after the LH surge provides meaningful clinical data that users can share with their healthcare providers, particularly in the context of suspected luteal phase deficiency or unexplained infertility.

Pricing, Access, and Practical Realities

The Oova analyzer attachment costs $149, with test strips at approximately $49.99 per pack of 10. With typical usage of 10 to 15 strips per cycle, monthly consumable costs range from $50 to $75. First-year total cost of ownership is approximately $750 to $1,050, placing Oova in the mid-range of quantitative fertility monitors. The device is HSA and FSA eligible.

Oova is FDA registered, a regulatory status that is distinct from FDA clearance. FDA registration means the company has listed the device with the FDA and complies with quality system regulations, but it has not undergone the same premarket review process as FDA-cleared devices. Users should understand this distinction: FDA registration establishes regulatory compliance but does not carry the same validation weight as 510(k) clearance.

The AI personalization feature improves with data, which means the system’s accuracy during the first one to two cycles may not reflect its full potential. Users should expect a learning period during which the AI is calibrating to their individual patterns. This is a trade-off inherent to personalized systems: they require data to become personalized, and early-cycle predictions may be less refined than those generated after several months of use.

Who the Oova Fertility Monitor Is Best For

Oova is best suited for women with irregular cycles or conditions like PCOS where standard population-threshold ovulation tests frequently fail. The AI personalization is most valuable precisely where fixed-threshold systems struggle most: in women whose hormonal patterns deviate from textbook norms. Women who have tried conventional ovulation predictor kits without success and want a system that adapts to their individual biology represent Oova’s ideal user.

Women interested in the intersection of artificial intelligence and reproductive health who want a technology-forward approach to fertility tracking will appreciate Oova’s machine learning methodology. Users who plan to track for multiple cycles will benefit most, as the AI refinement improves over time.

Women who want comprehensive multi-hormone tracking including estrogen and FSH may find Oova’s two-hormone panel insufficient. Users who need immediate accuracy from the first cycle rather than a system that improves over time may prefer monitors with validated fixed-threshold algorithms. Women on a tight budget may find Proov PdG strips ($40 to $60 per pack) a more affordable path to ovulation confirmation.

How the Oova Fertility Monitor Compares

The Mira Fertility Monitor ($199 plus consumables) and Inito Fertility Monitor ($149 plus consumables) both offer four-hormone panels (LH, E3G, PdG, FSH) compared to Oova’s two-hormone approach (LH, progesterone). These competitors provide a broader hormonal view and have published clinical validation studies. Oova’s differentiator is its AI personalization engine, which neither Mira nor Inito currently offers in the same form.

Proov PdG Test Strips ($40 to $60 per pack) focus exclusively on post-ovulatory progesterone confirmation at a fraction of Oova’s cost but lack LH prediction capability and AI personalization. Combining standard LH strips with Proov achieves a similar predict-and-confirm protocol for less money but without the personalized baselines that Oova provides.

Wearable cycle trackers like the Oura Ring Gen 3 offer completely passive monitoring through biometric signals but cannot measure specific hormone concentrations. The Oura Ring’s 2025 validation showed 96.4% ovulation detection across 1,155 cycles using physiology alone. For users who prioritize convenience over granular hormone data, wearables offer a compelling alternative.

Limitations and Open Questions

Oova’s two-hormone panel (LH and progesterone) is narrower than competitors offering four-hormone measurement. The absence of estrogen tracking means Oova cannot capture the pre-ovulatory estrogen rise that provides early warning of approaching ovulation, and the lack of FSH measurement limits its utility for women monitoring ovarian reserve.

The AI personalization model, while conceptually compelling, creates a cold-start problem: first-cycle predictions are based on limited individual data and may not be more accurate than conventional threshold-based tests. The system’s full value proposition requires patience and multiple cycles of data collection.

Oova’s FDA-registered status (versus FDA-cleared) means it has not undergone the same level of premarket review as some competitors. While registration is a legitimate regulatory pathway, users seeking the additional validation of 510(k) clearance may prefer FDA-cleared alternatives like Mira, Inito, or Proov.

Published peer-reviewed validation data specific to Oova’s AI personalization algorithm is limited compared to the clinical validation studies available for competitors. Independent clinical studies demonstrating that AI-personalized baselines improve conception rates or clinical outcomes compared to standard approaches would strengthen Oova’s evidence base.

What This Means for Your Health

The Oova Fertility Monitor represents the application of precision medicine principles to reproductive health. The idea that your hormone patterns should be interpreted against your own baseline rather than a population average aligns with the broader movement in healthcare toward individualized diagnostics and treatment. For women whose biology does not conform to textbook norms, this personalized approach may capture information that conventional tools miss.

Within Healthcare Discovery‘s Five Pillars framework, the AI-personalized approach recognizes that foundational health practices affect each woman’s hormonal patterns differently. How your sleep quality, stress levels, nutritional status, and exercise patterns influence your specific LH and progesterone trajectories is a deeply individual question. Oova’s longitudinal tracking, enhanced by AI learning, can help reveal these connections over time, showing how changes in your foundational health practices translate into measurable shifts in your cycle quality.

In the context of longevity science, reproductive hormone health serves as a sensitive early warning system for broader metabolic and cardiovascular health. Persistent anovulation, inadequate progesterone, and irregular cycles are associated with increased long-term risk for metabolic dysfunction and cardiovascular disease, two of the Four Shadows. By making hormone monitoring more personalized and accessible, tools like Oova contribute to the broader goal of identifying and addressing health risks earlier, when foundational interventions can still change the trajectory.

Frequently Asked Questions

What hormones does the Oova Fertility Monitor measure?
Oova measures two reproductive hormones: luteinizing hormone (LH) for ovulation prediction and progesterone for ovulation confirmation. The device provides quantitative concentrations through a smartphone-based reader. It does not measure estrogen metabolites (E3G) or follicle-stimulating hormone (FSH), which some competing monitors include.

How much does the Oova Fertility Monitor cost?
The Oova analyzer costs $149, with test strips at approximately $49.99 per pack of 10. Monthly consumable costs for typical use range from $50 to $75, with annual total cost of ownership between $750 and $1,050. The device is HSA and FSA eligible.

How does Oova’s AI personalization work?
Oova’s AI learns from your individual hormone data over successive cycles, establishing personalized baselines for your LH surge pattern and progesterone levels. Rather than comparing your results to population averages, the system adapts its predictions and interpretations to your specific biology. Accuracy improves with each cycle of data collected.

Is the Oova Fertility Monitor FDA cleared?
Oova is FDA registered, which is distinct from FDA cleared. FDA registration means the company has listed the device with the FDA and complies with quality system regulations. It has not undergone the 510(k) premarket review process that FDA-cleared devices complete. This is a legitimate regulatory pathway but carries a different level of premarket validation.

How long does it take for Oova’s AI to become accurate?
Oova’s AI personalization improves with data from each menstrual cycle. Most users can expect meaningful personalization to develop over two to three tracked cycles. First-cycle predictions are based on limited individual data and may not fully reflect the system’s potential. Users planning to track for several months will benefit most from the AI refinement.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.